Article Details
Retrieved on: 2020-12-10 14:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Agendia and <b>Roche</b> evaluate BluePrint's stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab. Agendia, Inc., a world ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here